Worse Wilms' Tumor Outcomes Associated With Chemical Complementarity for Multiple T-Cell Receptor CDR3-CMV Epitope

Kasey L Rigby1, Michael J Diaz2, Etienne C Gozlan2

  • 1University of Central Florida College of Medicine, Orlando, FL, U.S.A.

PubMed
Abstract

Insights

Cytomegalovirus (CMV) infections may be linked to poorer outcomes in pediatric Wilms' tumors. Analyzing T-cell receptor sequences suggests a novel method to identify patients who could benefit from CMV-targeted therapies.

Area of Science:

  • Oncology
  • Immunology
  • Virology

Background:

  • Wilms' tumors are common pediatric kidney cancers with generally good prognoses.
  • Viral infections are implicated in neoplasm development and may influence cancer survival rates.

Purpose of the Study:

  • To investigate the potential impact of cytomegalovirus (CMV) infections on Wilms' tumor outcomes.
  • To explore novel bioinformatics approaches for assessing viral influence in pediatric cancers.

Main Methods:

  • Utilized adaptive immune receptor, genomics, and bioinformatics techniques.
  • Compared T-cell receptor (TCR) complementarity determining region-3 (CDR3) sequences from Wilms' tumor specimens against known anti-CMV TCR CDR3s.
  • Applied a chemical complementarity scoring method between Wilms' tumor TCR CDR3s and CMV antigens.

Main Results:

  • Wilms' tumor cases with anti-CMV TCR CDR3s showed worse overall outcomes.
  • Higher chemical complementarity between tumor TCR CDR3s and CMV antigens correlated with poorer outcomes.
  • This suggests a potential link between CMV infection and adverse Wilms' tumor progression.

Conclusions:

  • Presents a novel method for assessing CMV infections in Wilms' tumor patients.
  • Identifies a potential biomarker for stratifying patients who may benefit from anti-CMV therapies.
  • Highlights the importance of considering viral factors in pediatric cancer treatment strategies.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K